Login to Your Account



Uniqure adds heart failure gene therapy with Inocard acquisition

By Cormac Sheridan
Staff Writer

Tuesday, August 12, 2014
Gene therapy pioneer Uniqure NV is moving into the field of complex disease, by purchasing Inocard GmbH, an early stage German start-up focused on congestive heart failure (CHF), in a cash-and-shares deal valued at €3 million (US$4.01 million) up front.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription